Table 3.
Best response to rescue therapy.
| VMP Inductionn=67 (%) |
VTP Inductionn=78 (%) |
|||||||
|---|---|---|---|---|---|---|---|---|
| Bz-based no. (%) | Len-based no. (%) | CC no. (%) | SC no. (%) | Bz-based no. (%) | Len-based no. (%) | CC no. (%) | SC no. (%) | |
| CR | 0(0) | 7(18.4) | 0 | 0 | 2 (14.3) | 6(15.4) | 1 (4.8) | 0 |
| nCR | 3(27.3) | 11(28.9) | 0 | 0 | 2 (14.3) | 9 (23.1) | 4 (19) | 0 |
| PR | 3(27.3) | 9(23.7) | 4 (40) | 0 | 1 (7.1) | 10 (25.6) | 3(14.3) | 0 |
| SD | 3 (27.3) | 6 (15.8) | 1 (10) | 0 | 4 (28.6) | 4 (10.3) | 5 (23.8) | 0 |
| NE | 0 (0) | 1 (2.6) | 2 (16.7) | 2 (40) | 0 (0) | 0 (0) | 1 (4.5) | 1 (33.3) |
| PD | 2 (18.2) | 3 (7.9) | 4 (40) | 3 (60) | 4 (28.6) | 6 (15.4) | 6 (28.6) | 2 (100) |
| ORR | 6 (54.5) | 27 (69.2) | 4 (40) | 0 | 5 (35.7) | 25 (64.1) | 8 (38.1) | 0 |
VMP: Bortezomib, Melphalan, and Prednisone; VTP: Bortezomib, Melphalan, and Thalidomide; CC: Conventional chemotherapy; SC: Supportive care; CR: Complete response; nCR: Near complete response, PR: Partial response; SD: Stable disease; NE: Not evaluable; PD: Progressive disease; ORR: Overall response rate (comprises partial response or better).